Overview
| Product name | Recombinant Human VSIG3/IgSF11 Protein |
|---|
| Catalog No. | RP01442 |
|---|
| Description | Recombinant Human VSIG3/IgSF11 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Leu23-Gly241) of human VSIG3/IGSF11 (Accession #NP_001015887.1) fused with a Fc, Avi tag at the C-terminus. |
|---|
| Bio-Activity | Measured by its binding ability in a functional ELISA. Immobilized Human VISTA (Catalog: RP01023) at 5μg/mL (100 μL/well) can bind Biotinylated Human VSIG3/IgSF11 (Catalog: RP01442) with a linear range of 0.02-2.03 μg/mL.
|
|---|
| Purity | > 95% by SDS-PAGE. |
|---|
| Endotoxin | <0.1EU/μg |
|---|
| Formulation | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. |
|---|
| Species | Human |
|---|
| Calculated MW | 50.99 kDa |
|---|
Background
Immunoglobulin superfamily member 11(IGSF11) is expressed on the plasma membrane in the testis and brain. These IGSF proteins undergo final modifications during capacitation and/or the acrosome reaction. IGSF proteins share significant homology with endothelial cell-selective adhesion molecule and coxsackievirus and adenovirus receptor, which mediates cell attachment and homotypic intercellular interactions. In clinical, the IGSF11 has been reported to overexpressed in colorectal cancers and hepatocellular carcinomas, as well as intestinal-type gastric cancers, compared to their corresponding non-cancerous tissues. The IGSF11 has also been found expressed abundantly in the testis and ovary and the IGSF11 can be used as a candidate of cancer-testis antigen.
Product information
| Synonym | BT-IgSF; CT119; CXADRL1; Igsf13; VSIG3; IGSF11 |
|---|
| Expression Host | HEK293 cells |
|---|
| Tag | C-hFc&Avi |
|---|
| Swiss-Prot | |
|---|
| Gene ID | |
|---|
Usage guide
| Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
|---|
| Reconstitution | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
|---|
* For research use only. Not for therapeutic or diagnostic purposes.
